Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

Background: Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved in 2020 as a first-line treatment for unresectable hepatocellular carcinoma (HCC). Atezo/Bev therapy is relativ...

Full description

Bibliographic Details
Main Authors: Yuji Eso, Haruhiko Takeda, Kojiro Taura, Atsushi Takai, Ken Takahashi, Hiroshi Seno
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Current Oncology
Subjects:
atezolizumab
bevacizumab
hepatocellular carcinoma
immune checkpoint inhibitor
vascular endothelial growth factor
neutrophil-to-lymphocyte ratio
Online Access:https://www.mdpi.com/1718-7729/28/5/352

Internet

https://www.mdpi.com/1718-7729/28/5/352

Similar Items